# Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

> **NCT02203825** · PHASE1 · COMPLETED · sponsor: **Celyad Oncology SA** · enrollment: 12 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** CM-CS1 T-cell infusion

## Key facts

- **NCT ID:** NCT02203825
- **Lead sponsor:** Celyad Oncology SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-06-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02203825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02203825, "Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02203825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*